TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Female or male aged ≥18 years~* History of type 2 diabetes mellitus for more than 12 months~* HbA1c≥7.0% and ≤11.0%~* Stable antidiabetic treatment during the last 12 weeks up to randomization~* eGFR 25-75 mL/minute/1.73m2, inclusive~* Micro or macroalbuminuria (UACR 30 - 3500 mg/g)~* Treatment with ACE inhibitor or an ARB for at least 3 months prior to screening~* Body mass index between 20 and 45 kg/m2~Exclusion Criteria:~* Any of the following CV/Vascular Diseases within 3 month prior to signing the consent at Visit 1:~  * Myocardial infarction~ * cardiac surgery or revascularization (CABG/PTCA)~ * unstable angina~ * unstable HF~ * New York Heart Association (NYHA) Class III-IV~ * transient ischemic attack (TIA) or significant cerebrovascular disease~ * unstable or previously undiagnosed arrhythmia~* Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency~* Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) \> 3X ULN~* Total Bilirubin (TB) \>2 mg/dL (34.2 μmol/L)~* History of acute kidney injury requiring renal replacement therapy (dialysis or ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis~* Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors~* Any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient or patient suspected or with confirmed poor protocol or medication compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin 10mg (Type: EXPERIMENTAL): Tablets administered orally once daily for 24 weeks
- Dapagliflozin 10mg + Saxagliptin 2.5mg (Type: EXPERIMENTAL): Tablets administered orally once daily for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Tablets administered orally once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-Market Study of the St. Jude Medical Angio-Seal™ V-Twist Integrated Platform (VIP) Vascular Closure Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient requires closure of femoral artery puncture resulting from arterial access procedure.~* Patient is ≥18 years of age.~* Patient is willing to provide written informed consent prior to study device use.~* Patient is willing and able to adhere to data collection and follow-up requirements.~Exclusion Criteria:~* Patient is participating in another clinical trial which has the potential to impact hemostasis.~* Patient has an active groin infection or systemic infection.~* Patient has undergone a vascular access procedure within the past 90 days.~* Patient has been previously enrolled in the study. (For patients undergoing multiple interventions within a timeframe of 90 days, only the initial procedure may constitute a study enrollment.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Angio-Seal VIP Vascular Closure (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Study of Surgical Staplers for the Treatment of Hemorrhoids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is able to understand and sign Informed Consent Form~* The subject is between 18-85 years of age.~* The subject has (symptomatic) Grade 2-3 Hemorrhoids and is eligible for stapled hemorrhoidopexy~Exclusion Criteria:~* The procedure is needed as revision hemorrhoid surgery.~* Any female patient, who is pregnant, suspected pregnant, or nursing.~* The participant has an active or a history of infection requiring antibiotics at the intended operative site within thirty (30) days prior to the planned surgery date.~* The participant is unable or unwilling to comply with the study requirements, follow-up schedule.~* The participant has a 1 year history of drug or alcohol abuse.~* The participant has a history of venous thrombosis or pulmonary embolism.~* The participant has a history of coagulopathy.~* The participant has taken aspirin, anti-coagulation and/or anti platelet therapies (e.g. Warfarin, Lovenox) within 7 days prior to the planned date of surgery.~* The participant has a history of fecal incontinence~* The participant has had injection therapy, infrared laser treatment or rubber band ligation for treatment of hemorrhoids within 1 month of screening~* The participant has co-morbidities which, in the opinion of the investigator, will not be appropriate for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- EEA Hemorrhoid and Prolapse Stapling Set (Type: EXPERIMENTAL): None
- Endosurgery Proximate PPH03 Stapling Set (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Determining the Prognostic Value of Continuous Intrathecal Infusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previous lumbar or thoracic spine surgery or lower thoracic/lumbar vertebral compression fracture~* Intractable pain of trunk (more than limbs)~* Patient who passed psychological evaluations as part of the usual clinical care prior to consideration of IDDS and are stable with current pain condition and medications~* Failed more conservative management.~Exclusion Criteria:~* Untreated coagulopathy or infection.~* Immune compromised state precluding having an implant.~* Allergic reactions to bupivacaine or fentanyl.~* Pregnancy~* Patients using more than 30 mg oral equivalents of morphine daily or who are unable to wean down below that dosage for more than 4 weeks before the prognostic intrathecal infusion test.~* Neurological deficits characterized as weakness in lower extremities with evidence of nerve damage~* Patients with cognitive disorders who would not be able to provide meaningful outcome responses

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Solution followed by Inactive Placebo Solution (Type: ACTIVE_COMPARATOR): Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml~6 hour washout followed by~Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline
- Inactive Placebo Solution followed by Active Solution (Type: PLACEBO_COMPARATOR): Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline~6 hour washout followed by~Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent asthma of a minimum of six months duration that has been stable for at least four weeks prior to screening~* Male and female children aged 4-11 years, inclusive, with predicted forced expiratory volume in 1 second (FEV1) 60-90%~* Ability to perform spirometry~* Demonstrate 12% airways reversibility~Exclusion Criteria:~* Require continuous treatment with beta-blockers, monoamine oxidase inhibitors, tricyclic antidepressants, anticholinergics, and/or systemic corticosteroids~* Presence of any non-asthmatic clinically-significant acute or uncontrolled chronic diseases

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Albuterol-HFA-BAI (Type: EXPERIMENTAL): ProAir(TM) HFA, Breath Actuated Inhalation Aerosol
- Placebo-HFA-BAI (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously confirmed histological diagnosis of locally advanced or metastatic papillary or follicular thyroid carcinoma, without anaplastic component. Tumor sample available for centralized exploratory analysis.~* Presence of one or more measurable lesions at least 1 cm in the longest diameter by spiral CT scan or 2 cm with conventional techniques.~* Progressive disease following RAI131 or patient unsuitable for RAI131 after surgery.~* Serum TSH \<0.5 mU/L.~Exclusion Criteria:~* Major surgery within 4 weeks before randomization.~* Prior chemotherapy within the last 4 weeks prior to randomization.~* RAI131 therapy within 3 months in patients with radioiodine uptake.~* Radiation therapy within the last 4 weeks prior to randomization (with the exception of palliative radiotherapy).~* Serum bilirubin \>1.5\*the upper limit of reference range (ULRR).~* Creatinine clearance \< 30 ml/min (calculated by Cockcroft-Gault formula).~* Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) greater than 2.5\*ULRR, or greater than 5.0\*ULRR if judged by the investigator to be related to liver metastases.~* Clinically significant cardiovascular event (eg myocardial infarction), superior vena cava \[SVC\] syndrome, New York Heart Association \[NYHA\] classification of heart failure \>II within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.~* History of arrhythmia (multifocal premature ventricular contractions \[PVCs\], bigeminy, trigeminy, ventricular tachycardia or uncontrolled atrial fibrillation), which is symptomatic or requires treatment (CTCAE grade 3), , or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication are permitted.~* Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vandetanib (ZD6474) (Type: EXPERIMENTAL): vandetanib (ZD6474) 300 mg per os once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with myelodysplastic syndrome, (MDS) according to WHO classification (\< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation~2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor (MUD) HLA-identity defined by the following markers: HLA-A, -B, -DRB1, DQB1.~3. Target graft size (unmanipulated) bone marrow: 2 to 10 x 106 CD34+ cells/kg BW recipient or at least 2 x 108 nucleated cells /kg BW or peripheral blood: 4 to 10 x 106 CD34+ cells/kg BW recipient~4. Age \> 18 and \< 60 years~5. Karnofsky Index \> 80 %~6. Adequate contraception in female patients of child-bearing potential~7. Written informed consent~Exclusion Criteria:~1. 'Secondary' or therapy-related MDS with known history of exposure to cytotoxic alkylating drugs and/or radiation therapy~2. Previous AML-induction therapy with more than two courses (e.g. in case of blast excess)~3. Previous allogeneic transplantation~4. Severe concomitant illnesses / medical conditions (e.g. impaired respiratory and/or cardiac function)~5. Known and manifested malignant involvement of the CNS~6. Active infectious disease~7. HIV- positivity or active hepatitis infection~8. Impaired liver function (Bilirubin \> upper normal limit; Transaminases \> 3.0 x upper normal limit)~9. Impaired renal function (Creatinine-clearance \< 60 ml/min; Serum Creatinine \> 1.5 x upper normal limit).~10. Pleural effusion or ascites \> 1.0 L~11. Pregnancy or lactation~12. Known hypersensitivity to treosulfan and/or fludarabine~13. Participation in another experimental drug trial within 4 weeks before study~14. Non-co-operative behaviour or non-compliance~15. Psychiatric diseases or conditions that might impair the ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treosulfan (Type: EXPERIMENTAL): Patients with myelodysplastic syndrome, (MDS) according to WHO classification (\< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of either OAG or OHT study eye, requiring IOP-lowering treatment~* Participant is currently a nonsmoker and has not smoked any nicotine-containing products within the previous 6 months~Exclusion Criteria:~* Current or anticipated enrollment in another investigational drug or device study~* Females who are pregnant, nursing, or planning a pregnancy during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimatoprost SR 10 μg (Type: EXPERIMENTAL): Participants will receive Bimatoprost SR 10 μg implant in the study eye on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
- LUMIGAN 0.01% (Type: OTHER): Participants will receive topical LUMIGAN 0.01% in the study eye once daily starting evening Dose on Day 1 and standard of care treatment in the fellow eye for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 1 to 5 years of age, previously vaccinated with three or four doses of IPV.~2. Healthy without obvious medical conditions that preclude entry of the subject into the study as established by the medical history and physical examination.~3. Written informed consent obtained from 1 or 2 parent(s) or legal guardian(s) as per country regulations.~Exclusion Criteria:~1. Previous vaccination against poliovirus outside the national immunization schedule.~2. Any confirmed or suspected immunosuppressive or known immunodeficient condition including human immunodeficiency virus (HIV) infection.~3. Family history of congenital or hereditary immunodeficiency.~4. Major congenital defects or serious uncontrolled chronic illness (neurologic, pulmonary, gastrointestinal, hepatic, renal, or endocrine).~5. Known allergy to any component of the study vaccines or to any antibiotics.~6. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~7. Acute severe febrile illness at day of vaccination deemed by the Investigator to be a contraindication for vaccination (the child can be included at a later time if within age window and all in/exclusion criteria are met.).~8. Member of the subject's household (living in the same house or apartment unit) has received OPV in the last 3 months.~9. Subject who, in the opinion of the Investigator, is unlikely to comply with the protocol or is inappropriate to be included in the study for the safety or the benefit-risk ratio of the subject.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Sabin mOPV2 1 dose (Type: EXPERIMENTAL): IPV-vaccinated children to receive 1 dose of SABIN mOPV2 (Group 1)
- SABIN mOPV2 2 doses (Type: EXPERIMENTAL): IPV-vaccinated children to receive 2 doses of SABIN mOPV2 (Group 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fluent in English~* At least eight (8) years of education~* Geriatric Depression Scale (GDS) (62) score \< 6~* Hachinski Ischemic Score ≤ 4~* Normal general cognitive function as well as 1) normal memory function, documented by MOCA score of 23 or greater, and a RBANS Delayed Memory Index score of 85 or greater.~Exclusion Criteria:~* Neurological disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or a history of significant head trauma or known structural brain abnormalities~* Major psychiatric disease or chronic unstable medical conditions~* History of drug abuse~* History of alcohol abuse (4 or greater drinks per day on average)~* Unable to complete MRI scans (no Pacemaker/Defibrillator)~* Known clinically significant abnormalities in B12 or thyroid function tests~* End Stage Renal Disease (ESRD)~* Hemodialysis (HD)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- AGB101 220 mg, then Placebo (Type: EXPERIMENTAL): AGB101 220 mg/day capsule, once daily dosing for 2 weeks. After a 4 week washout, to be followed by Placebo, given as a capsule, once daily dosing for 2 weeks.
- Placebo, then AGB101 220 mg (Type: EXPERIMENTAL): Placebo, given as a capsule, once daily for 2 weeks. After a 4 week washout, to be followed by AGB101 220 mg/day capsule, once daily dosing for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* infants \</=12 months of age~* laboratory confirmed diagnosis of influenza within 96 hours prior to first dose~* influenza symptoms for \</=96 hours prior to first dose~Exclusion Criteria:~* preterm infants less than 40 weeks (corrected for gestational age)~* weight less than 5th percentile for age (corrected for gestational age)~* concurrent gastrointestinal conditions that preclude enteric absorption of the drug~* bronchopulmonary dysplasia/chronic lung disease on assisted ventilation at time of enrollment~* active or uncontrolled respiratory, cardiac, hepatic, CNS or renal disease at baseline~* symptomatic inborn errors of metabolism

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Oseltamivir 3 mg (Type: EXPERIMENTAL): infants 3 to \<12 months
- Oseltamivir 2.5 mg (Type: EXPERIMENTAL): infants 1 to \<3 months of age
- Oseltamivir 2 mg (Type: EXPERIMENTAL): infants 0 to 30 days (post natal) of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete